Propanc Biopharma (NASDAQ:PPCB) Announces Quarterly Earnings Results

Propanc Biopharma (NASDAQ:PPCB) issued its quarterly earnings data on Friday. The company reported ($12.22) earnings per share for the quarter, FiscalAI reports.

Propanc Biopharma Trading Down 0.3%

Shares of PPCB traded down $0.01 on Friday, reaching $1.92. 9,307 shares of the company’s stock traded hands, compared to its average volume of 39,572. The stock has a market cap of $1.21 million, a PE ratio of -0.01 and a beta of 3.55. The stock’s 50 day simple moving average is $4.57 and its two-hundred day simple moving average is $20.32. Propanc Biopharma has a 52-week low of $1.63 and a 52-week high of $315.00.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Propanc Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 26th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Propanc Biopharma Company Profile

Propanc Biopharma, Inc. (NASDAQ:PPCB) is a clinical-stage biotechnology company focused on developing novel treatments for solid tumors, including pancreatic, ovarian and colorectal cancers. The company’s research is based on proenzyme therapy, an approach intended to selectively target cancer cells and cancer stem cells while limiting tumor growth, recurrence and metastasis. Propanc’s lead investigational product is PRP, also referred to as PRP-100, an intravenous formulation comprising the naturally occurring digestive proenzymes trypsinogen and chymotrypsinogen.